291. Hirschsprung disease, entire colon type Clinical trials / Disease details
Clinical trials : 12 / Drugs : 24 - (DrugBank : 15) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04904081 (ClinicalTrials.gov) | June 16, 2021 | 14/5/2021 | Feasibility of Use of Indocyanine Green in Pediatric Colorectal Surgery | The Use of Indocyanine Green Angiography in Pediatric Colorectal Surgery: A Feasibility Randomized Controlled Trial | Hirschsprung Disease;Anorectal Malformations | Drug: Indocyanine green | Lawson Health Research Institute | NULL | Recruiting | 1 Month | 7 Years | All | 12 | Phase 3 | Canada |
| 2 | NCT04598841 (ClinicalTrials.gov) | January 1, 2021 | 18/10/2020 | Nutrition Support for Hirschsprung Disease | A Multicentric Study on Pre-operative Nutritional Support for Hirschsprung's Disease | Nutrition Supporting;Hirschsprung Disease;Infants;Prospective Study | Dietary Supplement: supplement nutritional supporting | Tongji Hospital | NULL | Recruiting | 0 Years | 5 Years | All | 100 | N/A | China |
| 3 | ChiCTR2000035860 | 2020-10-01 | 2020-08-18 | Artificial intelligence for pathological grading system of ganglion cells for intraoperative rapid biopsy in Hirschsprung disease | Artificial intelligence for pathological grading system of ganglion cells for intraoperative rapid biopsy in Hirschsprung disease | Hirschsprung disease | Gold Standard:The speciemens and sections will be reveiwed by three senior pediatric gastroenterology pathologists under the novel pathological grading system of ganglion cells in Hirschsprung disease, and the results is regarded as the gold standard.;Index test:Artificial intelligence assisted whole-section patholgic diagnosis system; | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | NULL | Pending | 0 | 16 | Both | Target condition:138;Difficult condition:138 | China | |
| 4 | NCT04020939 (ClinicalTrials.gov) | March 16, 2020 | 2/7/2019 | The Role of Indocyanine Green Angiography Fluorescence on Intestinal Resections in Pediatric Surgery. | The Role of Indocyanine Green Angiography Fluorescence on Intestinal Resections in Pediatric Surgery. | Intestinal Atresia;Necrotizing Enterocolitis;Hirschsprung Disease;Gastroschisis;Intestinal Obstruction;Incarcerated Hernia;Intussusception;Malrotation;Volvulus;Meconium Ileus;Intestinal Perforation;Trauma | Device: SPY imaging;Drug: Indocyanine Green | St. Justine's Hospital | NULL | Completed | N/A | 16 Years | All | 35 | N/A | Canada |
| 5 | NCT03660176 (ClinicalTrials.gov) | January 2, 2019 | 4/9/2018 | Effects of Butyrate Enemas on Postoperative Intestinal Mobility Disorders in Hirschsprung's Disease | Effects of Butyrate Enemas on Postoperative Intestinal Mobility Disorders in Hirschsprung's | Hirschsprung's Disease | Drug: butyrate enemas + routine management;Other: routine management | Assistance Publique Hopitaux De Marseille | NULL | Not yet recruiting | N/A | 17 Years | All | 58 | Phase 3 | France |
| 6 | NCT03593252 (ClinicalTrials.gov) | September 1, 2018 | 22/5/2018 | Bowel Preparation in Elective Pediatric Intestinal Surgery | Mechanical Bowel Prep and Prophylactic Oral Antibiotic Use in Children: Implications for Intestinal Surgery Complications | Colostomy Stoma;Ileostomy - Stoma;Jejunostomy Stoma;Hirschprung's Disease;NEC;Inflammatory Bowel Diseases;Meconium Ileus;Bowel Obstruction | Drug: Senna;Drug: Sodium Picosulfate, Magnesium Oxide and Citric Acid;Drug: Erythromycin;Drug: Kanamycin;Drug: Cefazolin;Drug: Metronidazole;Other: Nil per os | McMaster University | NULL | Not yet recruiting | 6 Months | 18 Years | All | 48 | N/A | NULL |
| 7 | JPRN-UMIN000024993 | 2016/12/01 | 15/12/2016 | Study for efficacy of usage of enteral nutrient with immuno-balance modulation action in perioperative management of pediatric patients | Study for efficacy of usage of enteral nutrient with immuno-balance modulation action in perioperative management of pediatric patients - Efficacy in usage of enteral nutrient with immuno-balance modulation action | Hirschsprung's disease, Atresia ani, Congenital biliary dilatation, GERD | In the control group, the following enteral nutrient will be administered (breast milk or artificial milk for infants, Racol for infants). Dose and duration: Before surgery, the patient will take enteral nutrients at 60 to 100 kcal / kg per day for 3 days. After the surgery, enteral nutrition will restart within 2 to 3 days after surgery, and continue until 6th postoperative day. In contrast, immunomodulatory nutrition is administered in the test group. Dose and duration: Before surgery, the patient will take enteral nutrients at 60 to 100 kcal / kg per day for 3 days. After the surgery, enteral nutrition will restart within 2 to 3 days after surgery, and continue until 6th postoperative day. The study period is from December 1, 2016 to March 31, 2018. | University of Tsukuba Hospital | NULL | Pending | 6months-old | 48months-old | Male and Female | 10 | Not applicable | Japan |
| 8 | NCT02343562 (ClinicalTrials.gov) | October 2014 | 9/1/2015 | Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis | Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis | Hirschsprung Disease | Dietary Supplement: Probiotics;Dietary Supplement: Placebo | Cairo University | NULL | Unknown status | 6 Months | 12 Years | All | 40 | Phase 4 | Egypt |
| 9 | NCT02350088 (ClinicalTrials.gov) | January 2014 | 17/1/2015 | Fast-track Surgery in the Treatment of Hirschsprung's Disease | Fast-track Surgery in the Treatment of Hirschsprung's Disease | Surgery | Drug: probiotics;Drug: placebo | Tongji Hospital | Children's Hospital Boston | Recruiting | 1 Year | 18 Years | Both | 100 | N/A | China |
| 10 | NCT02216994 (ClinicalTrials.gov) | January 2013 | 6/8/2014 | A New Scoring System Improves Diagnostic Accuracy of Intestinal Dysganglionosis --a Prospective Study | Efficacy and Accuracy of a New Diagnostic Scoring System to Differentiate Hirschsprung Disease From Hirschsprung Disease Allied Disorders in the Patients With Suspected Intestinal Dysganglinosis: a Prospective Study | Hirschsprung Disease | Drug: high dose lactulose;Behavioral: conservative treatment;Drug: paraffin oil | Tongji Hospital | Jiangxi Provincial Children's Hospital | Recruiting | N/A | 3 Years | Both | 80 | N/A | China |
| 11 | NCT01934959 (ClinicalTrials.gov) | January 2008 | 21/8/2013 | A Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis | A Prospective Multicenter Randomized Controlled Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis | Probiotics;Hirschsprung's Disease Associated Enterocolitis | Drug: Bifico | Tongji Hospital | Anhui Provincial Hospital | Completed | 1 Month | 13 Years | Both | 60 | Phase 0 | NULL |
| 12 | NCT00630838 (ClinicalTrials.gov) | September 2006 | 28/2/2008 | Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC) | Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC) | Hirschsprung Disease | Drug: VSL#3;Drug: Placebo | University of Michigan | NULL | Completed | 1 Month | 12 Months | All | 62 | Phase 2 | United States |